Financial terms were not disclosed, although Nordion will leave an estimated US$18m in the company.
Best Medical has acquired all of MDS Nordion, with the exception of the TheraSphere business, which develops liver cancer therapeutics.
The firm bought another Nordion company, Ottawa-based Theratronics, four years ago.
Nordion made a decision in the 2010 financial year to restructure or exit this business, stating that it wanted to reduce complexity, manage costs and focus on growing areas of the business.
The 55 employees at MDS Nordion will transfer to Best Medical, which will also acquire the Belgian production facilities.
Nordion expects the transaction to be completed in the next few months.
Nordion sells Belgian operation
Best Medical to buy MDS Nordion, terms not revealed
You may also like
Manufacturing
ITT to acquire SPX FLOW in $4.8bn deal, expanding global leadership in engineered components and flow technologies
Read moreAcquisition strengthens ITT’s position in industrial, chemical, energy, health and nutrition markets, adding high-margin revenue, major aftermarket growth and $80m in expected synergies by year three
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
ITT to acquire SPX FLOW in $4.8bn deal, expanding global leadership in engineered components and flow technologies
Acquisition strengthens ITT’s position in industrial, chemical, energy, health and nutrition markets, adding high-margin revenue, major aftermarket growth and $80m in expected synergies by year three
Finance
EIB and Angelini Ventures launch €150m fund to boost European biotech, medtech and digital health startups
The EIB and Angelini Ventures will co-invest €150 million to scale innovative European healthtech companies. The deal marks the EIB’s first partnership with a corporate venture capital fund in the healthcare sector
Finance
Fresh capital flows into neurodegeneration, cancer and vascular-access developers
A string of funding rounds and strategic financing deals across Europe’s life-sciences sector is breathing new life into companies working on high-need treatments — from neurodegeneration to cancer and dialysis access